• Cucurbitacin I (JSI-124) STAT3 Assay Workflow

  2026-09-18

  Build a mechanism-first workflow with Cucurbitacin I (JSI-124), linking rapid STAT3 target engagement to apoptosis, invasion, chemosensitivity, and xenograft endpoints. The strategy also adapts the modular logic of human SAN-plexus assembloids without confusing cardiac model innovation with cancer pharmacology evidence.

• Wogonin, Macrophage Polarization, and Osteoarthritis

  2026-09-18

  A 2025 Phytomedicine study shows that wogonin alleviates experimental osteoarthritis by regulating macrophage polarization and inflammatory signaling through the LSD1–p65 axis. Its combination of DMM modeling, transcriptomics, CRISPR-edited macrophages, and joint-tissue analysis provides a mechanistic framework for studying immune–cartilage–bone crosstalk.

• Probenecid Workflows for Transporter and T-Cell Research

  2026-09-17

  Probenecid enables mechanism-aware studies of MRP-mediated drug efflux, pannexin-1 signaling, and neuroinflammatory injury. This workflow also shows how to use it cautiously as an exploratory perturbation alongside CD28–ARS2–PKM immunometabolism assays, without confusing transporter effects with validated T-cell splicing mechanisms.

• PD 0332991: CDK4/6 Workflow and Optimization

  2026-09-17

  Build Rb-aware experiments around PD 0332991, from dose-response and cell-cycle profiling to cisplatin-resistance studies. The workflow emphasizes pathway verification, combination-design controls, formulation discipline, and orthogonal readouts rather than relying on viability data alone.

• 3-Aminobenzamide: PARP Inhibition Workflows

  2026-09-16

  3-Aminobenzamide (PARP-IN-1) provides a practical pharmacological route to interrogate PARP-dependent stress responses in vascular, cardiac, renal, and host–virus models. This guide connects dose-finding, assay controls, and troubleshooting with the reference study’s paired macrodomain-mutant and wild-type coronavirus workflow.

• Torin2 Workflows for mTOR Signaling and Cell Death

  2026-09-16

  Torin2 combines subnanomolar mTOR potency with cell-based utility for viability, migration, apoptosis, and pathway studies. This practical guide connects mTOR inhibition with emerging Pol II-linked cell-death questions while emphasizing controls, solvent handling, and assay interpretation.

• Why mRNA Reporter Design Demands More Than Signal

  2026-09-15

  Firefly luciferase mRNA is more than a convenient reporter: it is a systems-level probe of delivery, translation, cellular energy, and transcript quality. This thought-leadership guide explains how Cap1, m1Ψ, poly(A) architecture, and emerging evidence on elongation and fidelity should shape translational mRNA workflows.

• Sulfisomidine: Mechanism, Assays, and Environmental Fate

  2026-09-15

  Sulfisomidine, also called sulfamethin, is a short-acting sulfonamide antibacterial agent and a research probe for folate-pathway inhibition and hPON1 enzyme kinetics. Its practical value spans antibacterial assays, oxidative stress regulation research, lipid metabolism pathway studies, and environmental transformation experiments, but each use requires explicit assay and matrix controls.

• Abiraterone Acetate: CYP17 Research Guide

  2026-09-14

  Abiraterone acetate is a CYP17 inhibitor used to study androgen biosynthesis pathway dependence in prostate cancer research. This guide separates product-specific assay benchmarks from evidence generated with patient-derived three-dimensional spheroids.

• Bufalin Targets STK33 in Triple-Negative Breast Cancer

  2026-09-14

  A 2025 Advanced Science study identifies STK33 as a binding target and degradation-sensitive dependency of Bufalin in triple-negative breast cancer. By combining affinity-based target discovery, genetic perturbation, mechanistic analysis, animal models, and patient-derived organoids, the work connects STK33 destabilization with suppression of tumor growth.

• ac4C Improves Synthetic mRNA Translation and Fidelity

  2026-09-13

  The reference study identifies N4-acetylcytidine (ac4C) as an alternative to m1Ψ that can increase synthetic mRNA protein output without increasing inflammatory responses. Its central mechanistic finding is that translation elongation rate, ribosome collisions, and quality-control pathways can determine mRNA yield even when ribosome loading is similar.

• AAPH Oxidative Stress Assay Workflows

  2026-09-12

  AAPH delivers a sustained, water-compatible peroxyl-radical challenge for erythrocyte hemolysis, lipid peroxidation, and antioxidant screening. This practical guide links assay design to the PRDX6–GPX4 ferroptosis pathway while separating useful model features from claims that require cellular or tumor validation.

• ARCA Cy3 EGFP mRNA (5-moUTP) Guide

  2026-09-11

  ARCA Cy3 EGFP mRNA (5-moUTP) is a direct-detection reporter for studying delivery, intracellular localization, and EGFP expression. This 5-methoxyuridine modified mRNA combines Cy3 fluorescence, ARCA capping, and a reported 5-moU formulation to support controlled mRNA transfection in mammalian cells.

• Rhodamine B: From Drift Tracer to Assay Signal

  2026-09-11

  Rhodamine B connects environmental spray-drift mapping with carefully controlled fluorescence workflows. This article explains how Basic Violet 10 converts transport and deposition into defensible assay data while identifying the limits of cross-domain interpretation.

• I-BET151: A Causal Map of BET Cancer Biology

  2026-09-10

  I-BET151 (GSK1210151A) can do more than suppress BET-dependent transcription: it can help researchers test causal links between enhancer control, tumor-state adaptation, apoptosis, and disulfidptosis. This article integrates the compound’s pharmacology with a recent prostate cancer study to develop a more discriminating assay strategy.

8703 records 1/581 page Next 12345 下5页 Last page